Sunday, September 15, 2019

   
 

Plenary Session

Faculty

   
Waldenstrom Award Lecture Award Recipient
   
Great Debates in Myeloma  
Moderators V Rajkumar/MV Mateos
   
Should RVD/KRD be considered the standard frontline induction regimen? P Richardson/K Stewart
Should MRD negativity be the end point of therapy? S Jagannath/J San Miguel
Will CAR-T cell therapy replace ASCT? P McCarthy/P Moreau
Is lenalidomide alone adequate for maintenance? P Voorhees/S Kastritis
Will ASCT remain a standard of care in 5 years? MV Mateos
What metric should be used for FDA/EMA drug approval? O Landgren/P Sonneveld
   
Clinical Trials in Progress  
Moderators D Reece/N Van De Donk
North America S Kumar/R Orlowski
Europe S Zweegman/T Facon
S. America V Hungria
Asia L Qui/K Shimizu
Australia A Spencer/ J Ho
   
Welcome to IMW18 Organizers of IMW18 
   
Closing Comments Organizers of IMW17
   
 
 

Workshop Organizers

Christopher Patterson
IMW 17 Secretariat

Dana Farber Cancer Institute
Mayor 548
450 Brookline Avenue
Boston, MA 02215
+1 617 632 6285

cpatterson1@partners.org

Join the IMS Today

Enjoy the

benefits of Membership

in the

International Myeloma Society

Become a Member Today

Housing & Registration

Accommodations


c/o SPARGO, Inc.
11208 Waples Mill Road
Suite 112
Fairfax, VA 22030 USA
888-788-1522 (US Toll free)
+ 1 703-449-6418 (International)

Reserve Now

Contact the IMS

International Myeloma Society

Lisa Sikkink, IMS Assistant

International Myeloma Society
Mayo Clinic
Siebens 6-60
200 First Street SW
Rochester, MN 55905
+1 507 284 3725

adminassistant@myelomasociety.org